Pfizer and BioNTech Choose Lead mRNA Vaccine Candidate Against COVID-19 and Commence Pivotal Phase 2/3 Global Study
Pfizer, a Bio Nebraska member, and BioNTech SE announced this week the start of a global 2/3 safety and efficacy clinical study for a COVID-19 vaccine, with two Nebraska locations included in the research. Read more